AnchorDx UriFind Bladder Cancer Test Gets FDA Breakthrough Device Designation
The FDA awarded AnchorDx a Breakthrough Device Designation for UriFind, an early detection test for bladder cancer based on urine DNA methylation detection.
Read More
Search Results for: bladder cancer
Birmingham University, Nonacus Partner to Develop Urine Test for Bladder Cancer
The urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Read More
Novel Urine Screening Test Can Detect New and Recurrent Bladder Cancer
A study found a new urine screening test using a novel K17 cancer biomarker can detect new bladder cancer in patients with blood in the urine.
Read MoreDecipher Identifies Bladder Cancer Patients Most Likely to Benefit from Neoadjuvant Immunotherapy
Patients with muscle-invasive bladder cancer who had the molecular subtype basal claudin low received the greatest benefit from Keytruda immunotherapy.
Read More
Pangea Licenses At-Home Urine Test for Bladder Cancer Detection
The test features a noninvasive, epigenetic-based option for collection at home or in a doctor’s office.
Read More